<DOC>
	<DOCNO>NCT00271804</DOCNO>
	<brief_summary>The purpose study find maximal tolerate dose Velcade give thalidomide patient myelodysplasia .</brief_summary>
	<brief_title>Study Velcade Thalidomide Patients With Myelodysplasia</brief_title>
	<detailed_description>Initial study use Velcade myelodysplasia early result demonstrate 35 % partial response 25 % stable disease . The combination Velcade thalidomide study patient multiple myeloma , patient myelodysplasia . The CRR MM patient 22 % , good safety profile . This phase 1 , prospective , open-label , dose escalation study evaluate DLT MTD velcade give combination thalidomide patient myelodysplasia . Treatment give outpatient . Patients receive 4 day Velcade ( day 1 , 4 , 8 , 11 ) 21 day thalidomide 50 mg/day 21 day cycle . There 3 cohort 3-6 patient , plus 10 additional patient . The tree dose level ill 0.7 , 1.0 1.3 mg/m2 . Patients may continue treat 6 cycle . Cycles 2-6 start within 2 week completion previous cycle . Disease response evaluate cycle 3 6 .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Myelodysplastic syndrome IPSS score 0.5 great May prior chemo/radiotherapy another malignancy myelodysplasia ECOG performance status 02 Life expectancy great 3 month Total bilirubin &lt; /+ 2xULN ALT AST &lt; /+ 3xULN Calculated creatinine clearance &gt; 30 ml/min Use appropriate method contraception study ANC &gt; 0.5 x 10 ( 9 ) Platelet count &gt; 30 x 10 ( 9 ) Consideration treatment 5 azacytidine encourage require Ejection fraction &lt; 40 % myocardial infarction within 6 month enrollment New York Heart Association Class III IV heart failure , uncontrolled angina , uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality Women pregnant breastfeed Major surgery within 4 week prior enrollment &gt; /= grade 2 peripheral neuropathy within 14 day prior enrollment Uncontrolled intercurrent illness Serious medical psychiatric illness could potentially interfere completion treatment Hypersensitivity bortezomib , boron , mannitol Received investigational drug within 14 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Myelodysplasia</keyword>
	<keyword>MDS</keyword>
	<keyword>Velcade</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Bortezomib</keyword>
</DOC>